Showing results (11-20 of 237) with videos related to

Sort By:
Pageof 24
JAMA Network Open|December 7, 2021
Misleading Reporting (Spin) in Noninferiority Randomized Clinical Trials in Oncology With Statistically Not Significant Results: A Systematic ReviewChiyo Ito, Atsushi Hashimoto, Kohei Uemura, et al.
Photodiagnosis and Photodynamic Therapy|August 21, 2023
Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (3rd report): Cost impact of transurethral resection of bladder tumor in JapanHideo Fukuhara, Yasuhiro Hagiwara, Koji Oba, et al.
International Journal of Cardiology. Heart & Vasculature|November 7, 2022
Identification of predictive factors interacting with heart rate reduction for potential beneficial clinical outcomes in chronic heart failure: A systematic literature review and <i>meta</i>-analysisAkira Yamashina, Masanori Nishikori, Hiroaki Fujimito, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|December 16, 2015
Does remnant gastric cancer really differ from primary gastric cancer? A systematic review of the literature by the Task Force of Japanese Gastric Cancer AssociationHideaki Shimada, Takeo Fukagawa, Yoshio Haga, et al.
Journal of Anesthesia|January 15, 2018
Vasoactive-inotropic score as a predictor of morbidity and mortality in adults after cardiac surgery with cardiopulmonary bypassYumiko Yamazaki, Koji Oba, Yoshiro Matsui, et al.
Psycho-Oncology|September 12, 2007
The domain structure of the EORTC QLQ-STO22 supported by Japanese validation dataSatoshi Morita, Adrian A Kaptein, Koji Oba, et al.
International Journal of Clinical Oncology|January 14, 2018
Meta-analysis of randomized clinical trials in the era of individual patient data sharingTakuya Kawahara, Musashi Fukuda, Koji Oba, et al.
Clinical Colorectal Cancer|March 13, 2017
mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design and RationaleNaoki Nagata, Hideyuki Mishima, Shuichi Kurosawa, et al.
Anticancer Research|July 15, 2009
Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancerKoji Oba, Michiya Kobayashi, Takanori Matsui, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|April 11, 2013
Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer AssociationHideaki Shimada, Tamaki Noie, Manabu Ohashi, et al.
Pageof 24